Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.

Abstract

We evaluated the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting. Patients with OAB symptoms for >or=3 months received tolterodine ER (4 mg q.d.) for 12 weeks. Among incontinent patients (n = 772), the most bothersome OAB symptoms were daytime frequency (28%), urgency urinary incontinence (UUI; 27%), nocturnal frequency (26%) and urgency (19%); among continent patients (n = 91), they were daytime frequency (47%), nocturnal frequency (42%) and urgency (10%). Sixty-nine per cent of patients had one or more comorbid conditions. By week 12, there were significant reductions in patients' most bothersome symptom: -80% for UUI, -78% for urgency episodes, -40% for nocturnal frequency and -30% for daytime frequency (p < 0.0001). The most common adverse events were dry mouth (10%) and constipation (4%). In primary care practice, bothersome OAB symptoms can be effectively and safely treated with tolterodine ER, even in patients with comorbid conditions.

• Authors: V Elinoff, T Bavendam, D B Glasser, M Carlsson, N Eyland, R Roberts
• Journal: International journal of clinical practice (Int J Clin Pract) Vol. 60 Issue 6 Pg. 745-51 (Jun 2006) ISSN: 1368-5031 [Print] India
• PMID: 16805763 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Benzhydryl Compounds
• Cresols
• Delayed-Action Preparations
• Muscarinic Antagonists
• Phenylpropanolamine
• Tolterodine Tartrate

Topics

• Adult
• Aged
• Aged, 80 and over
• Benzhydryl Compounds (administration & dosage)
• Cresols (administration & dosage)
• Delayed-Action Preparations
• Female
• Humans
• Male
• Middle Aged
• Muscarinic Antagonists (administration & dosage)
• Phenylpropanolamine (administration & dosage)
• Tolterodine Tartrate
• Urinary Bladder, Overactive (drug therapy)